ID   RD/VCR-F3
AC   CVCL_A2HQ
DR   cancercelllines; CVCL_A2HQ
DR   Wikidata; Q105510758
RX   PubMed=7309287;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pelvis, muscle; UBERON=UBERON_0001325.
DI   NCIt; C8971; Embryonal rhabdomyosarcoma
DI   ORDO; Orphanet_99757; Embryonal rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1649 ! RD
SX   Female
AG   7Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 7
//
RX   PubMed=7309287; DOI=10.1002/ijc.2910280403;
RA   Houghton J.A., Houghton P.J., Brodeur G.M., Green A.A.;
RT   "Development of resistance to vincristine in a childhood
RT   rhabdomyosarcoma growing in immune-deprived mice.";
RL   Int. J. Cancer 28:409-415(1981).
//